JP7900888B2 - 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 - Google Patents

自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Info

Publication number
JP7900888B2
JP7900888B2 JP2023526226A JP2023526226A JP7900888B2 JP 7900888 B2 JP7900888 B2 JP 7900888B2 JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023526226 A JP2023526226 A JP 2023526226A JP 7900888 B2 JP7900888 B2 JP 7900888B2
Authority
JP
Japan
Prior art keywords
antibody
nmosd
patient
months
vib551
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023526226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549075A5 (cg-RX-API-DMAC10.html
JP2023549075A (ja
Inventor
デュウェイ シェ
ジョン ラッチフォード
エリエゼル カッツ
ウィリアム リース
リ ヤン
Original Assignee
ビエラ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビエラ バイオ インコーポレイテッド filed Critical ビエラ バイオ インコーポレイテッド
Publication of JP2023549075A publication Critical patent/JP2023549075A/ja
Publication of JP2023549075A5 publication Critical patent/JP2023549075A5/ja
Priority to JP2026066113A priority Critical patent/JP2026120679A/ja
Application granted granted Critical
Publication of JP7900888B2 publication Critical patent/JP7900888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023526226A 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 Active JP7900888B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026066113A JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026066113A Division JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Publications (3)

Publication Number Publication Date
JP2023549075A JP2023549075A (ja) 2023-11-22
JP2023549075A5 JP2023549075A5 (cg-RX-API-DMAC10.html) 2024-11-07
JP7900888B2 true JP7900888B2 (ja) 2026-08-05

Family

ID=81384348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023526226A Active JP7900888B2 (ja) 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
JP2026066113A Pending JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026066113A Pending JP2026120679A (ja) 2020-10-29 2026-04-14 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Country Status (10)

Country Link
US (1) US20230287114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4237447A4 (cg-RX-API-DMAC10.html)
JP (2) JP7900888B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230097118A (cg-RX-API-DMAC10.html)
AU (1) AU2021368769A1 (cg-RX-API-DMAC10.html)
CA (1) CA3197022A1 (cg-RX-API-DMAC10.html)
IL (1) IL302294A (cg-RX-API-DMAC10.html)
MX (1) MX2023004794A (cg-RX-API-DMAC10.html)
TW (1) TW202233676A (cg-RX-API-DMAC10.html)
WO (1) WO2022094334A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lancet，2019年，Vol.394，pp,1352-1363

Also Published As

Publication number Publication date
MX2023004794A (es) 2023-09-15
TW202233676A (zh) 2022-09-01
AU2021368769A1 (en) 2023-06-08
WO2022094334A1 (en) 2022-05-05
IL302294A (en) 2023-06-01
KR20230097118A (ko) 2023-06-30
JP2026120679A (ja) 2026-07-22
CA3197022A1 (en) 2022-05-05
US20230287114A1 (en) 2023-09-14
JP2023549075A (ja) 2023-11-22
EP4237447A4 (en) 2024-07-17
AU2021368769A9 (en) 2024-05-30
EP4237447A1 (en) 2023-09-06

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260722

R150 Certificate of patent or registration of utility model

Ref document number: 7900888

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150